References
1.
Gunnar RM, Passamani ER, Bourdillon PD, et al. Guidelines for the
early management of patients with acute myocardial infarction: a
report of the American College of Cardiology/American Heart Association
Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular
Procedures (Subcommittee to Develop Guidelines for the Early Management
of Patients with Acute Myocardial Infarction) J Am Coll Cardiol
1990;16:249-92.
2.
Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the
management of patients with acute myocardial infarction: a report
of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (Committee on Management of Acute
Myocardial Infarction). J Am Coll Cardiol 1996;28:1328-428.
3.
Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines
for the management of patients with acute myocardial infarction:
a report of the American College of Cardiology/ American Heart Association
Task Force on Practice Guidelines (Committee on Management of Acute
Myocardial Infarction). J Am Coll Cardiol 1999;34:890-911.
4.
Braunwald E, Antman E, Beasley J, et al. ACC/AHA 2002 guideline
update for the management of patients with unstable angina and non–ST-segment
elevation myocardial infarction: summary article: a report of the
American College of Cardiology/American Heart Association Task Force
on Practice Guidelines (Committee on the Management of Patients
With Unstable Angina). J Am Coll Cardiol 2002;40:1366.
5. Mehta RH, Montoye CK, Gallogly M, et al, for
the GAP Steering Committee of the American College of Cardiology.
Improving quality of care for acute myocardial infarction: the Guidelines
Applied in Practice (GAP) initiative. JAMA 2002;287:1269-76.
6.
Jencks SF, Huff ED, Cuerdon T. Change in the quality of care delivered
to medicare beneficiaries, 1998-1999 to 2000-2001. JAMA 2003;289:305-12.
7.
Schneider EC, Zaslavsky AM, Epstein AM. Racial disparities in the
quality of care for enrollees in medicare managed care. JAMA 2002;287:1288-94.
8.
Libby P. Current concepts of the pathogenesis of the acute coronary
syndromes. Circulation 2001;104:365-72.
9.
Hamm CW, Bertrand M, Braunwald E. Acute coronary syndrome without
ST elevation: implementation of new guidelines. Lancet 2001;358:1533-8.
10.
Davies MJ. The pathophysiology of acute coronary syndromes. Heart
2000;83:361-6.
11.
Falk E. Plaque rupture with severe pre-existing stenosis precipitating
coronary thrombosis: characteristics of coronary atherosclerotic
plaques underlying fatal occlusive thrombi. Br Heart J 1983;50:127-34.
12.
Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography
predict the site of a subsequent myocardial infarction in patients
with mild-to-moderate coronary artery disease? Circulation 1988;78:1157-66.
13.
Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role
in atherosclerosis. JAMA 1999;282:2035-42.
14.
Rothwell PM, Villagra R, Gibson R, Donders RC, Warlow CP. Evidence
of a chronic systemic cause of instability of atherosclerotic plaques.
Lancet 2000;355:19-24.
15.
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis.
Circulation 2002;105:1135-43.
16.
Dahlbäck B. Blood coagulation. Lancet 2000;355:1627-32.
17.
Rosenberg RD, Aird WC. Vascular-bed: specific hemostasis and hypercoagulable
states. N Engl J Med 1999;340:1555-64.
18.
Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon
of ischemic cell death: 1. Myocardial infarct size vs duration of
coronary occlusion in dogs. Circulation 1977;56:786-94.
19.
Hasche ET, Fernandes C, Freedman SB, Jeremy RW. Relation between
ischemia time, infarct size, and left ventricular function in humans.
Circulation 1995;92:710-9.
20.
DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary
occlusion during the early hours of transmural myocardial infarction.
N Engl J Med 1980;303:897-902.
21. de Feyter PJ, van den Brand M, Serruys PW,
Wijns W. Early angiography after myocardial infarction: what have
we learned? Am Heart J 1985;109:194-9.
22.
DeWood MA, Stifter WF, Simpson CS, et al. Coronary arteriographic
findings soon after non–Q-wave myocardial infarction. N Engl
J Med 1986;315:417-23.
23.
Early effects of tissue-type plasminogen activator added to conventional
therapy on the culprit coronary lesion in patients presenting with
ischemic cardiac pain at rest: results of the Thrombolysis in Myocardial
Ischemia (TIMI IIIA) trial. Circulation 1993;87:38-52.
24.
Boersma E, Mercado N, Poldermans D, Gardien M, Vos J, Simoons ML.
Acute myocardial infarction. Lancet 2003;361:847-58.
25. The GUSTO investigators. An international randomized
trial comparing four thrombolytic strategies for acute myocardial
infarction. N Engl J Med 1993;329:673-82.
26.
The Global Use of Strategies to Open Occluded Coronary Arteries
(GUSTO III) Investigators. A comparison of reteplase with alteplase
for acute myocardial infarction. N Engl J Med 1997;337:1118-23.
27.
The Continuous Infusion versus Double-Bolus Administration of Alteplase
(COBALT) Investigators. A comparison of continuous infusion of alteplase
with double-bolus administration for acute myocardial infarction.
N Engl J Med 1997;337:1124-30.
28.
Single-bolus tenecteplase compared with front-loaded alteplase in
acute myocardial infarction: the ASSENT-2 double-blind randomised
trial. Assessment of the Safety and Efficacy of a New Thrombolytic
Investigators. Lancet 1999;354:716-22.
29.
Intravenous NPA for the Treatment of Infarcting Myocardium Early;
InTIME-II, a double-blind comparison of single-bolus lanoteplase
vs accelerated alteplase for the treatment of patients with acute
myocardial infarction. Eur Heart J 2000;21:2005-13.
30.
Topol EJ, for the GUSTO V Investigators. Reperfusion therapy for
acute myocardial infarction with fibrinolytic therapy or combination
reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa
inhibition: the GUSTO V randomised trial. Lancet 2001; 357:1905-14.
31.
Assessment of the Safety and Efficacy of a New Thrombolytic Regimen
(ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in
combination with enoxaparin, abciximab, or unfractionated heparin:
the ASSENT-3 randomised trial in acute myocardial infarction. Lancet
2001;358:605-13.
32.
Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein
IIb/IIIa receptor blockade on recovery of coronary flow and left
ventricular function after the placement of coronary-artery stents
in acute myocardial infarction. Circulation 1998;98:2695-701.
33.
White H, for the Hirulog and Early Reperfusion or Occlusion (HERO)-2
Trial Investigators. Thrombin-specific anticoagulation with bivalirudin
versus heparin in patients receiving fibrinolytic therapy for acute
myocardial infarction: the HERO-2 randomised vascutrial. Lancet
2001;358:1855-63.
34.
Brener SJ, Barr LA, Burchenal JE, et al, for the ReoPro and Primary
PTCA Organization and Randomized Trial (RAPPORT) Investigators.
Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa
blockade with primary angioplasty for acute myocardial infarction.
Circulation 1998;98:734-41.
35.
Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein
IIb/IIIa receptor blockade with abciximab on clinical and angiographic
restenosis rate after the placement of coronary stents following
acute myocardial infarction. J Am Coll Cardiol 2000;35:915-21.
36.
Montalescot G, Barragan P, Wittenberg O, et al, for the Abciximab
before Direct Angioplasty and Stenting in Myocardial Infarction
Regarding Acute and Long-Term Follow-up (ADMIRAL) Investigators.
Platelet glycoprotein IIb/IIIa inhibition with coronary stenting
for acute myocardial infarction. N Engl J Med 2001;344:1895-903.
37.
Zhu MM, Feit A, Chadow H, Alam M, Kwan T, Clark LT. Primary stent
implantation compared with primary balloon angioplasty for acute
myocardial infarction: a meta-analysis of randomized clinical trials.
Am J Cardiol 2001;88:297-301.
38.
Stone GW, Grines CL, Cox DA, et al, for the Controlled Abciximab
and Device Investigation to Lower Late Angioplasty Complications
(CADILLAC) Investigators. Comparison of angioplasty with stenting,
with or without abciximab, in acute myocardial infarction. N Engl
J Med 2002;346:957-66.
39.
Direct thrombin inhibitors in acute coronary syndromes: principal
results of a meta-analysis based on individual patients’ data.
Lancet 2002;359:294-302.
40.
Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous
thrombolytic therapy for acute myocardial infarction: a quantitative
review of 23 randomised trials. Lancet 2003; 361:13-20.
41.
Braunwald E, Pfeffer MA. Ventricular enlargement and remodeling
following acute myocardial infarction: mechanisms and management.
Am J Cardiol 1991;68:1D-6D.
42.
Pfeffer MA. Left ventricular remodeling after acute myocardial infarction.
Annu Rev Med 1995;46:455-66.
43.
Weisman HF, Healy B. Myocardial infarct expansion, infarct extension,
and reinfarction: pathophysiologic concepts. Prog Cardiovasc Dis
1987;30:73-110.
44. Weber KT. Aldosterone in congestive heart failure.
N Engl J Med 2001;345:1689-97.
45.
Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment
of over 1.5 million patients with myocardial infarction in the US
from 1990 through 1999: the National Registry of Myocardial Infarction
1, 2 and 3. J Am Coll Cardiol 2000;36: 2056-63.
46.
American Heart Association. Heart Disease and Stroke Statistics
— 2004 Update. Dallas, TX: American Heart Association; 2003.
Available at http://www.americanheart.org/presenter.jhtml?identifier=3000090.
Accessed November 15, 2003.
46a.Wiviott SD, Morrow DA, Giugliano RP, et al.
Performance of the thrombolysis in myocardial infarction risk index
for early acute coronary syndrome in the National Registry of Myocardial
Infarction: a simple risk index predicts mortality in both ST and
non-ST elevation myocardial infarction. J Am Coll Cardiol 2003;41:365A.
47.
Guidry UC, Evans JC, Larson MG, Wilson PW, Murabito JM, Levy D.
Temporal trends in event rates after Q-wave myocardial infarction:
the Framingham Heart Study. Circulation 1999;100: 2054-9.
48.
Goldberg RJ, Yarzebski J, Lessard D, Gore JM. A two-decades (1975
to 1995) long experience in the incidence, in-hospital and long-term
case-fatality rates of acute myocardial infarction: a community-wide
perspective. J Am Coll Cardiol 1999;33:1533-9.
49.
Rouleau JL, Talajic M, Sussex B, et al. Myocardial infarction patients
in the 1990s: their risk factors, stratification and survival in
Canada: the Canadian Assessment of Myocardial Infarction (CAMI)
Study. J Am Coll Cardiol 1996;27:1119-27.
50.
Executive Summary of The Third Report of The National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation,
and Treatment of High Blood Cholesterol in Adults (Adult Treatment
Panel III). JAMA 2001;285:2486-97.
51.
National Kidney Foundation practice guidelines for chronic kidney
disease: evaluation, classification, and stratification. Ann Intern
Med 2003;139:137-47.
52.
National Heart, Lung, and Blood Institute. Act in Time to Heart
Attack. Available at http://www.nhlbi.nih.gov/actintime, 2003. Accessed
May 15, 2003.
53.
Wenger NK. You’ve come a long way, baby: cardiovascular health
and disease in women: problems and prospects. Circulation 2004;109:558-60.
54.
American College of Cardiology. Guidelines Applied in Practice.
Available at http://www.acc.org/gap/gap.htm, 2003. Accessed May
15, 2003.
55.
American Heart Association. Get With the Guidelines. Available at
http://www.americanheart.org/presenter.jhtml?identifier=1165, 2003.
Accessed May 15, 2003.
56.
Topol EJ, Kereiakes DJ. Regionalization of care for acute ischemic
heart disease: a call for specialized centers. Circulation 2003;107:1463-6.
57.
Califf RM, Faxon DP. Need for centers to care for patients with
acute coronary syndromes. Circulation 2003;107:1467-70.
58.
Willerson JT. Editor’s commentary: centers of excellence.
Circulation 2003;107:1471-2.
59.
National Cholesterol Education Program. Third Report of the Expert
Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol
in Adults (Adult Treatment Panel III). NIH Pub. No. 02-5125. Bethesda,
MD: National Heart, Lung, and Blood Institute, 2002;284 pages. Guidelines,
Related Tools, and Patient Information available at http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm.
Accessed May 15, 2003.
60.
Wielgosz AT. What do we really know about secondary prevention after
myocardial infarction? Can J Cardiol 1995;11(Suppl A):31A-32A.
61. Ebrahim S, Davey Smith G. Multiple risk factor
interventions for primary prevention of coronary heart disease.
Cochrane Database Syst Rev 2000CD001561.
62.
Ross SD, Allen IE, Connelly JE, et al. Clinical outcomes in statin
treatment trials: a meta-analysis. Arch Intern Med 1999;159: 1793-802.
63.
Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V. Assessment
of cardiovascular risk by use of multiple-risk-factor assessment
equations: a statement for healthcare professionals from the American
Heart Association and the American College of Cardiology. Circulation
1999;100:1481-92.
64.
Risk Assessment. American Heart Association. Available at: http://www.americanheart.org/presenter.jhtml?identifier=3003499,
2004. Accessed May 15, 2003.
65.
Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for primary
prevention of cardiovascular disease and stroke: 2002 update: consensus
panel guide to comprehensive risk reduction for adult patients without
coronary or other atherosclerotic vascular diseases. American Heart
Association Science Advisory and Coordinating Committee. Circulation
2002;106:388-91.
66.
Wilson K, Gibson N, Willan A, Cook D. Effect of smoking cessation
on mortality after myocardial infarction: meta-analysis of cohort
studies. Arch Intern Med 2000;160:939-44.
67.
Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade
after myocardial infarction: systematic review and meta regression
analysis. BMJ 1999;318:1730-7.
68.
Smith SC, Blair SN, Bonow RO, et al. AHA/ACC scientific statement:
AHA/ACC guidelines for preventing heart attack and death in patients
with atherosclerotic cardiovascular disease: 2001 update: a statement
for healthcare professionals from the American Heart Association
and the American College of Cardiology. Circulation 2001;104:1577-9.
69.
Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines
for cardiovascular disease prevention in women. Circulation 2004;109:672-93.
70.
Treating tobacco use and dependence: a clinical practice guideline.
Office of the Surgeon General. Available at http://www.surgeongeneral.gov/tobacco,
2000. Accessed May 15, 2003.
71.
Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline
update for the management of patients with chronic stable angina:
a report of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (Committee to Update the 1999
Guidelines for the Management of Patients with Chronic Stable Angina).
Available at www.acc.org/clinical/guidelines/stable/stable.pdf,
2002. Accessed December 2, 2003.
72.
Chobanian AV, Bakris GL, Black HR, et al, for the National Heart,
Lung, and Blood Institute Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure, National
High Blood Pressure Education Program Coordinating Committee. The
seventh report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
JAMA 2003;289:2560-72.
73.
Pignone M, Mulrow CD. Evidence based management of hypertension:
Using cardiovascular risk profiles to individualise hypertensive
treatment. BMJ 2001;322:1164-6.
74.
Turnbull F. Blood Pressure Lowering Treatment Trialists’ Collaboration.
Effects of different blood-pressure-lowering regimens on major cardiovascular
events: results of prospectivelydesigned overviews of randomised
trials. Lancet 2003;362:1527-35.
75.
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive
drug treatment in older persons with isolated systolic hypertension:
final results of the Systolic Hypertension in the Elderly Program
(SHEP). JAMA 1991;265:3255-64.
76.
Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary
prevention of cardiovascular events: a summary of the evidence for
the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-72.
77.
U.S. Preventive Services Task Force. Aspirin for the primary prevention
of cardiovascular events: recommendation and rationale. Ann Intern
Med 2002;136:157-60.
78.
Peters RJ, Mehta SR, Fox KA, et al, for the Clopidogrel in Unstable
angina to prevent Recurrent Events (CURE) Trial Investigators. Effects
of aspirin dose when used alone or in combination with clopidogrel
in patients with acute coronary syndromes: observations from the
Clopidogrel in Unstable angina to prevent Recurrent Events (CURE)
study. Circulation 2003; 108:1682-7.
79.
Hung J. Medical Issues Committee of the National Heart Foundation
of Australia. Aspirin for cardiovascular disease prevention. Med
J Aust 2003;179:147-52.
80.
Dracup K, Alonzo AA, Atkins JM, et al. The physician’s role
in minimizing prehospital delay in patients at high risk for acute
myocardial infarction: recommendations from the National Heart Attack
Alert Program (Working Group on Educational Strategies to Prevent
Prehospital Delay in Patients at High Risk for Acute Myocardial
Infarction). Ann Intern Med 1997;126:645-51.
81.
Hedges JR, Feldman HA, Bittner V, et al, for the REACT Study Group.
Impact of community intervention to reduce patient delay time on
use of reperfusion therapy for acute myocardial infarction: Rapid
Early Action for Coronary Treatment (REACT) trial. Acad Emerg Med
2000;7:862-72.
82.
Canto JG, Zalenski RJ, Ornato JP, et al, for the National Registry
of Myocardial Infarction 2 Investigators. Use of emergency medical
services in acute myocardial infarction and subsequent quality of
care: observations from the National Registry of Myocardial Infarction
2. Circulation 2002;106:3018-23.
83.
Goldberg R, Goff D, Cooper L, et al. Age and sex differences in
presentation of symptoms among patients with acute coronary disease:
the REACT Trial. Rapid Early Action for Coronary Treatment. Coron
Artery Dis 2000;11:399-407.
84.
Hutchings CB, Mann NC, Daya M, et al. Rapid Early Action for Coronary
Treatment Study. Patients with chest pain calling 9-1-1 or self-transporting
to reach definitive care: which mode is quicker? Am Heart J 2004;147:35-41.
85.
Becker L, Larsen MP, Eisenberg MS. Incidence of cardiac arrest during
self-transport for chest pain. Ann Emerg Med 1996;28: 612-6.
86.
Brown AL, Mann NC, Daya M, et al. Demographic, belief, and situational
factors influencing the decision to utilize emergency medical services
among chest pain patients: Rapid Early Action for Coronary Treatment
(REACT) study. Circulation 2000;102: 173-8.
87.
Goff DC, Feldman HA, McGovern PG, et al, for the Rapid Early Action
for Coronary Treatment (REACT) Study Group. Prehospital delay in
patients hospitalized with heart attack symptoms in the United States:
the REACT trial. Am Heart J 1999;138: 1046-57.
88.
Herlitz J, Karlson BW, Liljeqvist JA, Strömbom U, Holmberg
S. Early identification of acute myocardial infarction and prognosis
in relation to mode of transport to hospital. Am J Emerg Med 1992;10:406-12.
89.
Ho MT, Eisenberg MS, Litwin PE, Schaeffer SM, Damon SK. Delay between
onset of chest pain and seeking medical care: the effect of public
education. Ann Emerg Med 1989;18:727-31.
90.
Dracup K, Moser DK, Eisenberg M, Meischke H, Alonzo AA, Braslow
A. Causes of delay in seeking treatment for heart attack symptoms.
Soc Sci Med 1995;40:379-92.
91.
Herlitz J, Blohm M, Hartford M, et al. Follow-up of a 1-year media
campaign on delay times and ambulance use in suspected acute myocardial
infarction. Eur Heart J 1992;13:171-7.
92.
Luepker RV, Raczynski JM, Osganian S, et al. Effect of a community
intervention on patient delay and emergency medical service use
in acute coronary heart disease: the Rapid Early Action for Coronary
Treatment (REACT) Trial. JAMA 2000;284:60-7.
93.
Wright RS, Kopecky SL, Timm M, et al, for the Wabasha Heart Attack
Team. Impact of community-based education on health care evaluation
in patients with acute chest pain syndromes: the Wabasha Heart Attack
Team (WHAT) project. Fam Pract 2001; 18:537-9.
94.
Access to Timely and Optimal Care of Patients with Acute Coronary
Syndromes - Community Planning Considerations: a report by the National
Heart Attack Alert Program. J Thromb Thrombolysis 1998;6:19-46.
95. Leslie WS, Urie A, Hooper J, Morrison CE. Delay
in calling for help during myocardial infarction: reasons for the
delay and subsequent pattern of accessing care. Heart 2000;84:137-41.
96. Simon AB, Feinleib M, Thompson HK. Components
of delay in the pre-hospital phase of acute myocardial infarction.
Am J Cardiol 1972;30:476-82.
97.
Alonzo AA. The impact of the family and lay others on care-seeking
during life-threatening episodes of suspected coronary artery disease.
Soc Sci Med 1986;22:1297-311.
98.
Guidelines 2000 for cardiopulmonary resuscitation and emergency
cardiovascular care: part 12: from science to survival: strengthening
the chain of survival in every community. The American Heart Association
in collaboration with the International Liaison Committee on Resuscitation.
Circulation 2000;102:I358-70.
99.
McDermott MM, Mandapat AL, Moates A, et al. Knowledge and attitudes
regarding cardiovascular disease risk and prevention in patients
with coronary or peripheral arterial disease. Arch Intern Med 2003;163:2157-62.
100. Canto JG, Shlipak MG, Rogers WJ, et al. Prevalence,
clinical characteristics, and mortality among patients with myocardial
infarction presenting without chest pain. JAMA 2000;283:3223-9.
101.
Faxon D, Lenfant C. Timing is everything: motivating patients to
call 9-1-1 at onset of acute myocardial infarction. Circulation
2001;104:1210-1.
102.
Guidelines 2000 for cardiopulmonary resuscitation and emergency
cardiovascular care: part 7: the era of reperfusion: section 1:
acute coronary syndromes (acute myocardial infarction). The American
Heart Association in collaboration with the International Liaison
Committee on Resuscitation. Circulation 2000;102:I172-203.
103.
U.S. Department of Health and Human Services. Public Health Service.
National Institutes of Health. National Heart, Lung, and Blood Institute.
NIH Publication No. 01-3525. September 2001. Available at: http://www.nhlbi.nih.gov/health/public/heart/mi/
core_bk.pdf. Accessed December 16, 2002.
104.
U.S. Department of Health and Human Services. Public Health Service.
National Institutes of Health. National Heart, Lung, and Blood Institute.
NIH Publication No. 01-3526. November 2001. Available at: http://www.nhlbi.nih.gov/health/public/heart/mi/
core_sp.pdf. Accessed December 16, 2002.
105.
U.S. Department of Health and Human Services. Public Health Service.
National Institutes of Health. National Heart, Lung, and Blood Institute.
NIH Publication No. 01-3667. September 2001. Available at: http://www.nhlbi.nih.gov/health/public/heart/mi/
wallet.pdf. Accessed December 16, 2002.
106.
U.S. Department of Health and Human Services. Public Health Service.
National Institutes of Health. National Heart, Lung, and Blood Institute.
NIH Publication No. 01-3669. September 2001. Available at: http://www.nhlbi.nih.gov/health/public/heart/mi/
act_ plan.pdf. Accessed December 16, 2002.
107. U.S. Department of Health and Human Services.
Public Health Service. National Institutes of Health. National Heart,
Lung, and Blood Institute. NIH Publication No. 01-3313. September
2001. Available at: http://www.nhlbi.nih.gov/health/prof/heart/mi/
provider.pdf. Accessed December 16, 2002.
108.
Act in Time to Heart Attack Signs: Physician Quick Reference Tool
for Palm OS. Department of Health and Human Services. Public Health
Service. National Institutes of Health. National Heart, Lung, and
Blood Institute. 2001. Available at: http://hin.nhlbi.nih.gov/haac_palm/haac_palm.htm.
Accessed Decmeber 16, 2002.
109.
U.S. Department of Health and Human Services. Public Health Service.
National Institutes of Health. National Heart, Lung, and Blood Institute.
NIH Publication No. 01-3646. September 2001. Available at: http://www.nhlbi.nih.gov/health/public/heart/mi/
poster.pdf. Accessed Decmeber 16, 2002.
110.
Deleted in press.
111.
Goff DC, Sellers DE, McGovern PG, et al. Knowledge of heart attack
symptoms in a population survey in the United States: the REACT
Trial. Rapid Early Action for Coronary Treatment. Arch Intern Med
1998;158:2329-38.
112.
Welsh RC, Ornato J, Armstrong PW. Prehospital management of acute
ST-elevation myocardial infarction: a time for reappraisal in North
America. Am Heart J 2003;145:1-8.
113.
Goldberg RJ, Steg PG, Sadiq I, et al. Extent of, and factors associated
with, delay to hospital presentation in patients with acute coronary
disease (the GRACE registry). Am J Cardiol 2002; 89:791-6.
114.
Finnegan JR, Meischke H, Zapka JG, et al. Patient delay in seeking
care for heart attack symptoms: findings from focus groups conducted
in five U.S. regions. Prev Med 2000;31:205-13.
115.
Feldman HA, Proschan MA, Murray DM, et al. Statistical design of
REACT (Rapid Early Action for Coronary Treatment), a multisite community
trial with continual data collection. Control Clin Trials 1998;19:391-403.
116.
McKinley S, Moser DK, Dracup K. Treatment-seeking behavior for acute
myocardial infarction symptoms in North America and Australia. Heart
Lung 2000;29:237-47.
117.
Rucker D, Brennan T, Burstin H. Delay in seeking emergency care.
Acad Emerg Med 2001;8:163-9.
118.
Sheifer SE, Gersh BJ, Yanez ND, Ades PA, Burke GL, Manolio TA. Prevalence,
predisposing factors, and prognosis of clinically unrecognized myocardial
infarction in the elderly. J Am Coll Cardiol 2000;35:119-26.
119.
Kannel WB. Silent myocardial ischemia and infarction: insights from
the Framingham Study. Cardiol Clin 1986;4:583-91.
120.
Rathore SS, Weinfurt KP, Gersh BJ, Oetgen WJ, Schulman KA, Solomon
AJ. Treatment of patients with myocardial infarction who present
with a paced rhythm. Ann Intern Med 2001;134:644- 51.
121.
Cummins RO, Ornato JP, Thies WH, Pepe PE. Improving survival from
sudden cardiac arrest: the “chain of survival” concept:
a statement for health professionals from the Advanced Cardiac Life
Support Subcommittee and the Emergency Cardiac Care Committee, American
Heart Association. Circulation 1991;83: 1832-47.
122.
Cummins RO, Eisenberg MS, Hallstrom AP, Litwin PE. Survival of out-of-hospital
cardiac arrest with early initiation of cardiopulmonary resuscitation.
Am J Emerg Med 1985;3:114-9.
123.
Weisfeldt ML, Becker LB. Resuscitation after cardiac arrest: a 3-
phase time-sensitive model. JAMA 2002;288:3035-8.
124.
Stapczynski JS, Svenson JE, Stone CK. Population density, automated
external defibrillator use, and survival in rural cardiac arrest.
Acad Emerg Med 1997;4:552-8.
125.
Becker LB, Ostrander MP, Barrett J, Kondos GT. Outcome of CPR in
a large metropolitan area: where are the survivors? Ann Emerg Med
1991;20:355-61.
126.Lombardi
G, Gallagher J, Gennis P. Outcome of out-of-hospital cardiac arrest
in New York City: the Pre-Hospital Arrest Survival Evaluation (PHASE)
Study. JAMA 1994;271:678-83.
127.
White RD, Asplin BR, Bugliosi TF, Hankins DG. High discharge survival
rate after out-of-hospital ventricular fibrillation with rapid defibrillation
by police and paramedics. Ann Emerg Med 1996;28:480-5.
128.
White RD, Hankins DG, Bugliosi TF. Seven years’ experience
with early defibrillation by police and paramedics in an emergency
medical services system. Resuscitation 1998;39:145-51.
129.
Bunch TJ, White RD, Gersh BJ, et al. Long-term outcomes of outof-
hospital cardiac arrest after successful early defibrillation. N
Engl J Med 2003;348:2626-33.
130.
Stiell IG,Wells GA, Field BJ, et al. Improved out-of-hospital cardiac
arrest survival through the inexpensive optimization of an existing
defibrillation program: OPALS study phase II. Ontario Prehospital
Advanced Life Support. JAMA 1999;281:1175-81.
131.
Caffrey SL, Willoughby PJ, Pepe PE, Becker LB. Public use of automated
external defibrillators. N Engl J Med 2002;347:1242-7.
132.
Dracup K, Moser DK, Guzy PM, Taylor SE, Marsden C. Is cardiopulmonary
resuscitation training deleterious for family members of cardiac
patients? Am J Public Health 1994;84:116-8.
133.
Dracup K, Moser DK, Taylor SE, Guzy PM. The psychological consequences
of cardiopulmonary resuscitation training for family members of
patients at risk for sudden death. Am J Public Health 1997;87:1434-9.
134.
Chen MA, Eisenberg MS, Meischke H. Impact of in-home defibrillators
on postmyocardial infarction patients and their significant others:
an interview study. Heart Lung 2002;31:173-85.
135.
Home Automatic External Defibrillator Trial. National Heart, Lung,
and Blood Institute (NHLBI). Available at: http:// www.clinicaltrials.gov/ct/show/NCT00047411?order=46.
2004. NLM Identifier: NCT00047411. Accessed December 22, 2003.
136.
Hallstrom AP, Cobb LA, Johnson E, Copass MK. Dispatcher assisted
CPR: implementation and potential benefit: a 12-year study. Resuscitation
2003;57:123-9.
137. Cummins RO. From concept to standard-of-care?
Review of the clinical experience with automated external defibrillators.
Ann Emerg Med 1989;18:1269-75.
138.
Cummins RO, Schubach JA, Litwin PE, Hearne TR. Training lay persons
to use automatic external defibrillators: success of initial training
and one-year retention of skills. Am J Emerg Med 1989;7:143-9.
139.
Mosesso VN, Davis EA, Auble TE, Paris PM, Yealy DM. Use of automated
external defibrillators by police officers for treatment of out-of-hospital
cardiac arrest. Ann Emerg Med 1998;32:200-7.
140.
Valenzuela TD, Roe DJ, Nichol G, Clark LL, Spaite DW, Hardman RG.
Outcomes of rapid defibrillation by security officers after cardiac
arrest in casinos. N Engl J Med 2000;343:1206- 9.
141.
Page RL, Joglar JA, Kowal RC, et al. Use of automated external defibrillators
by a U.S. airline. N Engl J Med 2000;343:1210-6.
142.
Nichol G, Hallstrom AP, Kerber R, et al. American Heart Association
report on the second public access defibrillation conference, April
17-19, 1997. Circulation 1998;97:1309-14.
143.
Nichol G, Hallstrom AP, Ornato JP, et al. Potential cost-effectiveness
of public access defibrillation in the United States. Circulation
1998;97:1315-20.
144.
Kerber RE, Becker LB, Bourland JD, et al. Automatic external defibrillators
for public access defibrillation: recommendations for specifying
and reporting arrhythmia analysis algorithm performance, incorporating
new waveforms, and enhancing safety: statement for health professionals
from the American Heart Association Task Force on Automatic External
Defibrillation, Subcommittee on AED Safety and Efficacy. Circulation
1997;95:1677-82.
145.
Weisfeldt ML, Kerber RE, McGoldrick RP, et al, for the Automatic
Defibrillation Task Force. Public access to defibrillation. Am J
Emerg Med 1996;14:684-92.
146.
Weisfeldt ML, Kerber RE, McGoldrick RP, et al, for the Automatic
External Defibrillation Task Force. American Heart Association Report
on the Public Access Defibrillation Conference December 8-10, 1994.
Circulation 1995;92:2740-7.
147.
Weisfeldt ML, Kerber RE, McGoldrick RP, et al. Public access defibrillation:
a statement for healthcare professionals from the American Heart
Association Task Force on Automatic External Defibrillation. Circulation
1995;92:2763.
148. Deleted in press.
149.
Ornato JP, Racht EM, Fitch JJ, Berry JF. The need for ALS in urban
and suburban EMS systems. Ann Emerg Med 1990; 19:1469-70.
150.
Stout J, Pepe PE, Mosesso VN. All-advanced life support vs tiered-response
ambulance systems. Prehosp Emerg Care 2000;4:1-6.
151. Eisenberg MJ, Topol EJ. Prehospital administration
of aspirin in patients with unstable angina and acute myocardial
infarction. Arch Intern Med 1996;156:1506-10.
152.
ISIS-4 (Fourth International Study of Infarct Survival) Collaborative
Group. ISIS-4: a randomised factorial trial assessing early oral
captopril, oral mononitrate, and intravenous magnesium sulphate
in 58,050 patients with suspected acute myocardial infarction. Lancet
1995;345:669-85.
153.
Hutter AM, Weaver WD. 31st Bethesda Conference: emergency cardiac
care: task force 2: acute coronary syndromes: section 2A–prehospital
issues. J Am Coll Cardiol 2000;35:846-53.
154.
Lau J, Ioannidis J, Balk E, et al. Evaluation of Technologies for
Identifying Acute Cardiac Ischemia in Emergency Departments. Evidence
Report/Technology Assessment Number 26. (Prepared by the New England
Medical Center Evidence-based Practice Center under Contract No.
290-97-0019). AHRQ Publication No. 01-E006, Rockville, MD: Agency
for Healthcare Research and Quality, May 2001.
155.
Armstrong PW, Collen D, Antman E. Fibrinolysis for acute myocardial
infarction: the future is here and now. Circulation 2003;107:2533-7.
156.
Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group.
Indications for fibrinolytic therapy in suspected acute myocardial
infarction: collaborative overview of early mortality and major
morbidity results from all randomised trials of more than 1000 patients.
Lancet 1994;343:311-22.
157.
Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto
Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment
in acute myocardial infarction. Lancet 1986;1:397-402.
158.
Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety
of tenecteplase in combination with the low-molecular-weight heparin
enoxaparin or unfractionated heparin in the prehospital setting:
the Assessment of the Safety and Efficacy of a New Thrombolytic
Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction.
Circulation 2003;108:135-42.
159.
Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated
vs hospital-initiated thrombolytic therapy: the Myocardial Infarction
Triage and Intervention trial. JAMA 1993;270:1211-6.
160.
Hermens WT, Willems GM, Nijssen KM, Simoons ML. Effect of thrombolytic
treatment delay on myocardial infarct size. Lancet 1992;340:1297.
161.
Gersh BJ, Anderson JL. Thrombolysis and myocardial salvage: results
of clinical trials and the animal paradigm: paradoxic or predictable?
Circulation 1993;88:296-306.
162.
Newby LK, Rutsch WR, Califf RM, et al, for the GUSTO-1 Investigators.
Time from symptom onset to treatment and outcomes after thrombolytic
therapy. J Am Coll Cardiol 1996;27:1646-55.
163.
Milavetz JJ, Giebel DW, Christian TF, Schwartz RS, Holmes DR, Gibbons
RJ. Time to therapy and salvage in myocardial infarction. J Am Coll
Cardiol 1998;31:1246-51.
164.
Chareonthaitawee P, Gibbons RJ, Roberts RS, Christian TF, Burns
R, Yusuf S, for the CORE investigators (Collaborative Organisation
for RheothRx Evaluation). The impact of time to thrombolytic treatment
on outcome in patients with acute myocardial infarction. Heart 2000;84:142-8.
165.
McNeill AJ, Cunningham SR, Flannery DJ, et al. A double-blind placebo
controlled study of early and late administration of recombinant
tissue plasminogen activator in acute myocardial infarction. Br
Heart J 1989;61:316-21.
166.
Castaigne AD, Hervé C, Duval-Moulin AM, et al. Prehospital
use of APSAC: results of a placebo-controlled study. Am J Cardiol
1989;64:30A-33A; discussion.
167.
Barbash GI, Roth A, Hod H, et al. Improved survival but not left
ventricular function with early and prehospital treatment with tissue
plasminogen activator in acute myocardial infarction. Am J Cardiol
1990;66:261-6.
168.
Schofer J, Büttner J, Geng G, et al Prehospital thrombolysis
in acute myocardial infarction. Am J Cardiol 1990;66:1429-33.
169.
McAleer B, Ruane B, Burke E, et al. Prehospital thrombolysis in
a rural community: short- and long-term survival. Cardiovasc Drugs
Ther 1992;6:369-72.
170.
Grampian Region Early Anistreplase Trial (GREAT) Group. Feasibility,
safety, and efficacy of domiciliary thrombolysis by general practitioners:
BMJ 1992;305:548-53.
171.
The European Myocardial Infarction Project Group. Prehospital thrombolytic
therapy in patients with suspected acute myocardial infarction.
N Engl J Med 1993;329:383-9.
172.
Morrow DA, Antman EM, Sayah A, et al. Evaluation of the time saved
by prehospital initiation of reteplase for ST-elevation myocardial
infarction: results of The Early Retavase- Thrombolysis in Myocardial
Infarction (ER-TIMI) 19 trial. J Am Coll Cardiol 2002;40:71-7.
173.
Bonnefoy E, Lapostolle F, Leizorovicz A, et al for the Comparison
of Angioplasty and Prehospital Thrombolysis in Acute Myocardial
Infarction Study Group. Primary angioplasty versus prehospital fibrinolysis
in acute myocardial infarction: a randomised study. Lancet 2002;360:825-9.
174.
Spinler SA, Mikhail PA. Prehospital-initiated thrombolysis. Ann
Pharmacother 1997;31:1339-46.
175.
Karagounis L, Ipsen SK, Jessop MR, et al. Impact of field-transmitted
electrocardiography on time to in-hospital thrombolytic therapy
in acute myocardial infarction. Am J Cardiol 1990;66:786-91.
176.
Steg PG, Bonnefoy E, Chabaud S, et al. Impact of Time to Treatment
on Mortality After Prehospital Fibrinolysis or Primary Angioplasty:
data from the CAPTIM randomized clinical trial. Circulation 2003;108:2851-6.
177.
Widimský P, Budesinský T,Vorác D, et al. Long
distance transport for primary angioplasty vs immediate thrombolysis
in acute myocardial infarction: final results of the randomized
national multicentre trial-PRAGUE-2. Eur Heart J 2003;24:94-104.
178.
Deleted in press.
179.
Emergency department: rapid identification and treatment of patients
with acute myocardial infarction. National Heart Attack Alert Program
Coordinating Committee, 60 Minutes to Treatment Working Group. Ann
Emerg Med 1994;23:311-29.
180.
Cannon CP, Antman EM, Walls R, Braunwald E. Time as an adjunctive
agent to thrombolytic therapy. J Thromb Thrombolysis 1994;1:27-34.
181.
Weaver WD, Litwin PE, Martin JS, et al, for the MITI Project Group.
Effect of age on use of thrombolytic therapy and mortality in acute
myocardial infarction. J Am Coll Cardiol 1991;18:657- 62.
182. Gibler WB, Kereiakes DJ, Dean EN, et al.
Prehospital diagnosis and treatment of acute myocardial infarction:
a north-south perspective. The Cincinnati Heart Project and the
Nashville Prehospital TPA Trial. Am Heart J 1991;121:1-11.
183. Pedley DK, Bissett K, Connolly EM, et al.
Prospective observational cohort study of time saved by prehospital
thrombolysis for ST elevation myocardial infarction delivered by
paramedics. BMJ 2003;327:22-6.
184. Hochman JS, Sleeper LA, White HD, et al,
for the Should We Emergently Revascularize Occluded Coronaries for
Cardiogenic Shock (SHOCK) Investigators. One-year survival following
early revascularization for cardiogenic shock. JAMA 2001;285:190-2.
185. Cannon CP. Time to treatment: a crucial factor
in thrombolysis and primary angioplasty. J Thromb Thrombolysis 1996;3:249-255.
186. Steg PG, Goldberg RJ, Gore JM, et al, for
the GRACE Investigators. Baseline characteristics, management practices,
and in-hospital outcomes of patients hospitalized with acute coronary
syndromes in the Global Registry of Acute Coronary Events (GRACE).
Am J Cardiol 2002;90:358-63.
187.
Storrow AB, Gibler WB. Chest pain centers: diagnosis of acute coronary
syndromes. Ann Emerg Med 2000;35:449-61.
188.
Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of
acute cardiac ischemia in the emergency department. N Engl J Med
2000;342:1163-70.
189.
Jesse RL, Kontos MC. Evaluation of chest pain in the emergency department.
Curr Probl Cardiol 1997;22:149-236.
190.
Karcz A, Korn R, Burke MC, et al. Malpractice claims against emergency
physicians in Massachusetts: 1975-1993. Am J Emerg Med 1996;14:341-5.
191.
Graff L. Missed MI diagnosis. Ann Emerg Med 1994;23:141-2.
192.
McCarthy BD, Beshansky JR, D’Agostino RB, Selker HP. Missed
diagnoses of acute myocardial infarction in the emergency department:
results from a multicenter study. Ann Emerg Med 1993;22:579-82.
193.
Tatum JL, Jesse RL, Kontos MC, et al. Comprehensive strategy for
the evaluation and triage of the chest pain patient. Ann Emerg Med
1997;29:116-25.
194.
Tatum JL. Cost effective nuclear scanning in a comprehensive and
systematic approach to the evaluation of chest pain in the emergency
department. Md Med J 1997;Suppl:25-9.
195.
Ornato JP. Chest pain emergency centers: improving acute myocardial
infarction care. Clin Cardiol 1999;22:IV3-9.
196.
Newby LK, Storrow AB, Gibler WB, et al. Bedside multimarker testing
for risk stratification in chest pain units: the chest pain evaluation
by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study.
Circulation 2001;103:1832-7.
197.
Lateef F, Storrow AB, Gibler BW, Liu T. Heart emergency room: effective
for both geriatric and younger patients. Singapore Med J 2001;42:259-63.
198.
Lateef F, Storrow AB, Malone K, Liu T, Gibler BW. Comparison of
a 6-hour and 9-hour protocol for evaluation of moderate-to-low risk
chest pain patients in an emergency department diagnostic unit.
Singapore Med J 2001;42:052-6.
199.
Gibler WB. Chest pain units: do they make sense now? Ann Emerg Med
1997;29:168-71.
200.
Gibler WB. Evaluation of chest pain in the emergency department.
Ann Intern Med 1995;123:315; discussion 317.
201.
Gibler WB. Chest pain evaluation in the ED: beyond triage. Am J
Emerg Med 1994;12:121-2.
202.
Gibler WB. Evaluating patients with chest pain in the ED: improving
speed, efficiency, and cost-effectiveness, or teaching an old dog
new tricks. Ann Emerg Med 1994;23:381-2.
203.
Hoekstra JW, Gibler WB, Levy RC, et al. Emergency-department diagnosis
of acute myocardial infarction and ischemia: a cost analysis of
two diagnostic protocols. Acad Emerg Med 1994;1:103-10.
204.
Hoekstra JW, Hedges JR, Gibler WB, Rubison RM, Christensen RA, for
the National Cooperative CK-MB Project Group. Emergency department
CK-MB: a predictor of ischemic complications. Acad Emerg Med 1994;1:17-27.
205.
Cannon CP, Hand MH, Bahr R, et al, for the. National Heart Attack
Alert Program (NHAAP) Coordinating Committee Critical Pathways Writing
Group. Critical pathways for management of patients with acute coronary
syndromes: an assessment by the National Heart Attack Alert Program.
Am Heart J 2002;143:777- 89.
206.
Zalenski RJ, Selker HP, Cannon CP, et al. National Heart Attack
Alert Program position paper: chest pain centers and programs for
the evaluation of acute cardiac ischemia. Ann Emerg Med 2000;35:462-71.
207.
Lambrew CT,Weaver WD, Rogers WJ, Bowlby LJ, Rubison RM, French WJ.
Hospital protocols and policies that may delay early identification
and thrombolytic therapy of acute myocardial infarction patients.
J Thromb Thrombolysis 1996;3:301-306.
208.
Farkouh ME, Smars PA, Reeder GS, et al, for the Chest Pain Evaluation
in the Emergency Room (CHEER) Investigators. A clinical trial of
a chest-pain observation unit for patients with unstable angina.
N Engl J Med 1998;339:1882-8.
209.
Deleted in press.
210.
Charney P. Coronary artery disease in young women: the menstrual
cycle and other risk factors. Ann Intern Med 2001;135: 1002-4.
211.
Hasdai D, Porter A, Rosengren A, Behar S, Boyko V, Battler A. Effect
of gender on outcomes of acute coronary syndromes. Am J Cardiol
2003;91:1466-9–A6.
212.
Kudenchuk PJ, Maynard C, Martin JS, Wirkus M, Weaver WD. Comparison
of presentation, treatment, and outcome of acute myocardial infarction
in men versus women (the Myocardial Infarction Triage and Intervention
Registry) Am J Cardiol 1996;78:9-14.
213. Goldberg RJ, McCormick D, Gurwitz JH,Yarzebski
J, Lessard D, Gore JM. Age-related trends in short- and long-term
survival after acute myocardial infarction: a 20-year population-based
perspective (1975-1995). Am J Cardiol 1998;82:1311-7.
214.
Meischke H, Dulberg EM, Schaeffer SS, Henwood DK, Larsen MP, Eisenberg
MS. ‘Call fast, Call 911’: a direct mail campaign to
reduce patient delay in acute myocardial infarction. Am J Public
Health 1997;87:1705-9.
215.
McSweeney JC, Cody M, O’Sullivan P, Elberson K, Moser DK,
Garvin BJ. Women’s early warning symptoms of acute myocardial
infarction. Circulation 2003;108:2619-23.
216.
Bonow RO, Mitch WE, Nesto RW, et al. Prevention Conference VI: Diabetes
and Cardiovascular Disease: Writing Group V: management of cardiovascular-renal
complications. Circulation 2002;105:e159-64.
217.
Levy DE. How transient are transient ischemic attacks? Neurology
1988;38:674-7.
218. Sloan MA, Gore JM. Ischemic stroke and intracranial
hemorrhage following thrombolytic therapy for acute myocardial infarction:
a risk-benefit analysis. Am J Cardiol 1992;69:21A-38A.
219. Hochman JH, Gersh BJ. Acute myocardial infarction.
In: Topol EJ, ed. Textbook of Cardiovascular Medicine. 2nd ed. Philadelphia,
PA: Lippincott, Williams, and Wilkins; 2002:438.
220.
Spodick DH. Diagnostic electrocardiographic sequences in acute pericarditis:
significance of PR segment and PR vector changes. Circulation 1973;48:575-80.
221.
Menown IB, Mackenzie G, Adgey AA. Optimizing the initial 12- lead
electrocardiographic diagnosis of acute myocardial infarction. Eur
Heart J 2000;21:275-83.
222.
Mauri F, Gasparini M, Barbonaglia L, et al. Prognostic significance
of the extent of myocardial injury in acute myocardial infarction
treated by streptokinase (the GISSI trial). Am J Cardiol 1989;63:1291-5.
223.
Antman EM, Rutherford JD. Coronary care medicine: a practical approach.
Boston, MA: Martinus Nijhoff Publishing;1986:81.
224.
Effects of tissue plasminogen activator and a comparison of early
invasive and conservative strategies in unstable angina and non–Q-wave
myocardial infarction: results of the TIMI IIIB Trial. Thrombolysis
in Myocardial Ischemia. Circulation 1994;89: 1545-56.
225.
Matetzky S, Freimark D, Chouraqui P, et al. Significance of ST segment
elevations in posterior chest leads (V7 to V9) in patients with
acute inferior myocardial infarction: application for thrombolytic
therapy. J Am Coll Cardiol 1998;31:506-11.
226.
Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003
guideline update for the clinical application of echocardiography:
a report of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update
the 1997 Guidelines for the Clinical Application of Echocardiography).
American College of Cardiology Web Site. Available at: www.acc.org/clinical/guidelines/echo/index.pdf,
2003. Accessed August 4, 2003.
227.
Goldman L, Cook EF, Brand DA, et al. A computer protocol to predict
myocardial infarction in emergency department patients with chest
pain. N Engl J Med 1988;318:797-803.
228.
Wang K, Asinger RW, Marriott HJ. ST-segment elevation in conditions
other than acute myocardial infarction. N Engl J Med 2003;349:2128-35.
229. Sgarbossa EB, Pinski SL, Barbagelata A, et
al, for the GUSTO-1 (Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary Arteries) Investigators.
Electrocardiographic diagnosis of evolving acute myocardial infarction
in the presence of left bundle-branch block. N Engl J Med 1996;334:481-7.
230.
Sgarbossa EB. Value of the ECG in suspected acute myocardial infarction
with left bundle-branch block. J Electrocardiol 2000;33(Suppl):87-92.
231.
Luepker RV, Apple FS, Christenson RH, et al. Case definitions for
acute coronary heart disease in epidemiology and clinical research
studies: a statement from the AHA Council on Epidemiology and Prevention;
AHA Statistics Committee; World Heart Federation Council on Epidemiology
and Prevention; the European Society of Cardiology Working Group
on Epidemiology and Prevention; Centers for Disease Control and
Prevention; and the National Heart, Lung, and Blood Institute. Circulation
2003;108:2543-9.
232.
Adams JE, Abendschein DR, Jaffe AS. Biochemical markers of myocardial
injury: is MB creatine kinase the choice for the 1990s? Circulation
1993;88:750-63.
233.
Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction
redefined: a consensus document of the Joint European Society of
Cardiology/American College of Cardiology Committee for the redefinition
of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.
234.
Wu AH, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R. National
Academy of Clinical Biochemistry Standards of Laboratory Practice:
recommendations for the use of cardiac markers in coronary artery
diseases. Clin Chem 1999;45:1104-21.
235.
Ohman EM, Armstrong PW, White HD, et al for the Global Use of Strategies
To Open Occluded Coronary Arteries (GUSTO III) Investigators. Risk
stratification with a point-of-care cardiac troponin T test in acute
myocardial infarction. Am J Cardiol 1999;84:1281-6.
236.
Tanasijevic MJ, Cannon CP, Wybenga DR, et al. Myoglobin, creatine
kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis
for acute myocardial infarction: results from TIMI 10A. Am Heart
J 1997;134:622-30.
237.
Puleo PR, Meyer D, Wathen C, et al. Use of a rapid assay of subforms
of creatine kinase-MB to diagnose or rule out acute myocardial infarction.
N Engl J Med 1994;331:561-6.
238.
Antman EM, Sacks DB, Rifai N, McCabe CH, Cannon CP, Braunwald E.
Time to positivity of a rapid bedside assay for cardiac- specific
troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis
in Myocardial Infarction (TIMI) 11A substudy. J Am Coll Cardiol
1998;31:326-30.
239.
Klocke FJ, Baird MG, Bateman TM, et al. ACC/AHA/ASNC guidelines
for the clinical use of cardiac radionuclide imaging: a report of
the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the
1995 Guidelines for the Clinical Use of Radionuclide Imaging). American
College of Cardiology Web Site. Available at http://www.acc.org/clinical/
guidelines/radio/rni_fulltext.pdf, 2003. Accessed August 18, 2003.
240.
Lee KL, Woodlief LH, Topol EJ, et al, for the GUSTO-I Investigators.
Predictors of 30-day mortality in the era of reperfusion for acute
myocardial infarction: results from an international trial of 41,021
patients. Circulation 1995;91:1659-68.
241.
Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for
rapid initial triage of patients with ST-elevation myocardial infarction:
an InTIME II substudy. Lancet 2001;358:1571-5.
242.
Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for
ST-elevation myocardial infarction: a convenient, bedside, clinical
score for risk assessment at presentation: an intravenous nPA for
treatment of infarcting myocardium early II trial substudy. Circulation
2000;102:2031-7.
243.
Selker HP, Griffith JL, Beshansky JR, et al. Patient-specific predictions
of outcomes in myocardial infarction for real-time emergency use:
a thrombolytic predictive instrument. Ann Intern Med 1997;127:538-56.
244.
Selker HP, Beshansky JR, Griffith JL, for the TPI Trial Investigators.
Use of the electrocardiograph-based thrombolytic predictive instrument
to assist thrombolytic and reperfusion therapy for acute myocardial
infarction: a multicenter, randomized, controlled, clinical effectiveness
trial. Ann Intern Med 2002;137: 87-95.
245.
Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM, for the
National Registry of Myocardial Infarction 2 Participants. Sex-based
differences in early mortality after myocardial infarction. N Engl
J Med 1999;341:217-25.
246.
Brass LM, Lichtman JH, Wang Y, Gurwitz JH, Radford MJ, Krumholz
HM. Intracranial hemorrhage associated with thrombolytic therapy
for elderly patients with acute myocardial infarction: results from
the Cooperative Cardiovascular Project. Stroke 2000;31:1802-11.
247.
Krumholz HM, Pasternak RC, Weinstein MC, et al L. Cost effectiveness
of thrombolytic therapy with streptokinase in elderly patients with
suspected acute myocardial infarction. N Engl J Med 1992;327:7-13.
248.
Maroko PR, Radvany P, Braunwald E, Hale SL. Reduction of infarct
size by oxygen inhalation following acute coronary occlusion. Circulation
1975;52:360-8.
249.
Madias JE, Hood WB. Reduction of precordial ST-segment elevation
in patients with anterior myocardial infarction by oxygen breathing.
Circulation 1976;53:I198-200.
250. Fillmore SJ, Shapiro M, Killip T. Arterial
oxygen tension in acute myocardial infarction: serial analysis of
clinical state and blood gas changes. Am Heart J 1970;79:620-9.
251. Aubier M, Trippenbach T, Roussos
C. Respiratory muscle fatigue during cardiogenic shock. J Appl Physiol
1981;51:499-508.
252.
Abrams J. Hemodynamic effects of nitroglycerin and long-acting nitrates.
Am Heart J 1985;110:216-24.
253.
Winbury MM. Redistribution of left ventricular blood flow produced
by nitroglycerin: an example of integration of the macroand microcirculation.
Circ Res 1971;28(Suppl 1):140-7.
254.
Gorman MW, Sparks HV. Nitroglycerin causes vasodilatation within
ischaemic myocardium. Cardiovasc Res 1980;14:515-21.
255. Deleted in press.
256. Come PC, Pitt B. Nitroglycerin-induced severe
hypotension and bradycardia in patients with acute myocardial infarction.
Circulation 1976;54:624-8.
257.
Kinch JW, Ryan TJ. Right ventricular infarction. N Engl J Med 1994;330:1211-7.
258.
Cheitlin MD, Hutter AM, Brindis RG, et al. ACC/AHA expert consensus
document on the use of sildenafil (Viagra) in patients with cardiovascular
disease. American College of Cardiology/ American Heart Association.
J Am Coll Cardiol 1999;33:273-82.
259.
Antman EM, Braunwald E. Acute myocardial infarction. In: Braunwald
E, Zipes DP, Libby P, eds. Heart disease: a textbook of cardiovascular
medicine, 6th ed. Philadelphia, PA: WB Saunders Co Ltd; 2001:1114-1251.
260.
Hochman JS, Califf RM. Acute myocardial infarction. In: Smith TW.
Cardiovascular therapeutics: a companion to Braunwald’s heart
disease, 2nd ed. Philadelphia, PA: WB Saunders Co Ltd; 2001:235-291.
261. ISIS-2 (Second International Study of Infarct
Survival) Collaborative Group. Randomised trial of intravenous streptokinase,
oral aspirin, both, or neither among 17,187 cases of suspected acute
myocardial infarction: ISIS-2. Lancet 1988;2:349- 60.
262.
Roux S, Christeller S, Lüdin E. Effects of aspirin on coronary
reocclusion and recurrent ischemia after thrombolysis: a metaanalysis.
J Am Coll Cardiol 1992;19:671-7.
263.
Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis
of randomised trials of antiplatelet therapy for prevention of death,
myocardial infarction, and stroke in high-risk patients. BMJ 2002;324:71-86.
264.
Sagar KA, Smyth MR. A comparative bioavailability study of different
aspirin formulations using on-line multidimensional chromatography.
J Pharm Biomed Anal 1999;21:383-92.
265.
Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during
and after myocardial infarction: an overview of the randomized trials.
Prog Cardiovasc Dis 1985;27:335-71.
266.
Randomised trial of intravenous atenolol among 16 027 cases of suspected
acute myocardial infarction: ISIS-1. First International Study of
Infarct Survival Collaborative Group. Lancet 1986;2:57- 66.
267.
The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction:
patient population. Am J Cardiol 1985;56:10G- 14G.
268.
The TIMI Study Group. Comparison of invasive and conservative strategies
after treatment with intravenous tissue plasminogen activator in
acute myocardial infarction: results of the thrombolysis in myocardial
infarction (TIMI) phase II trial. N Engl J Med 1989;320:618-27.
269.
Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred
beta-blockade following thrombolytic therapy in patients with acute
myocardial infarction: results of the Thrombolysis in Myocardial
Infarction (TIMI) II-B Study. Circulation 1991;83: 422-37.
270.
Van de Werf F, Janssens L, Brzostek T, et al. Short-term effects
of early intravenous treatment with a beta-adrenergic blocking agent
or a specific bradycardiac agent in patients with acute myocardial
infarction receiving thrombolytic therapy. J Am Coll Cardiol 1993;22:407-16.
271.
Pfisterer M, Cox JL, Granger CB, et al. Atenolol use and clinical
outcomes after thrombolysis for acute myocardial infarction: the
GUSTO-I experience. Global Utilization of Streptokinase and TPA
(alteplase) for Occluded Coronary Arteries. J Am Coll Cardiol 1998;32:634-40.
272.
Kloner RA, Hale S. Unraveling the complex effects of cocaine on
the heart. Circulation 1993;87:1046-7.
273. Dargie HJ. Effect of carvedilol on outcome
after myocardial infarction in patients with left-ventricular dysfunction:
the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
274.
De Luca G, Suryapranata H, Zijlstra F, et al, for the ZWOLLE Myocardial
Infarction Study Group. Symptom-onset-to-balloon time and mortality
in patients with acute myocardial infarction treated by primary
angioplasty. J Am Coll Cardiol 2003;42:991-7.
275.
De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay
to treatment and mortality in primary angioplasty for acute myocardial
infarction: every minute of delay counts. Circulation 2004;109:1223-5.
275a.Williams DO. Treatment delayed is treatment
denied. Circulation 2004;109:1806-8.
276.
Davies CH, Ormerod OJ. Failed coronary thrombolysis. Lancet 1998;351:1191-6.
277.
Ito H, Okamura A, Iwakura K, Masuyama T, et al. Myocardial perfusion
patterns related to thrombolysis in myocardial infarction perfusion
grades after coronary angioplasty in patients with acute anterior
wall myocardial infarction. Circulation 1996;93: 1993-9.
278.
Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular
obstruction by magnetic resonance imaging in patients with acute
myocardial infarction. Circulation 1998;97: 765-72.
279.
Zeymer U, Tebbe U, Essen R, Haarmann W, Neuhaus KL, for the ALKK-Study
Group. Influence of time to treatment on early infarct-related artery
patency after different thrombolytic regimens. Am Heart J 1999;137:34-8.
280.
Gibson CM. Has my patient achieved adequate myocardial reperfusion?
Circulation 2003;108:504-7.
281.
Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez-Sendon
J, for the GRACE Investigators. Practice variation and missed opportunities
for reperfusion in ST-segment-elevation myocardial infarction: findings
from the Global Registry of Acute Coronary Events (GRACE). Lancet
2002;359:373-7.
282.
Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary
angioplasty and intravenous thrombolytic therapy for acute myocardial
infarction: a quantitative review. JAMA 1997; 278:2093-8.
283.
Hasdai D, Behar S,Wallentin L, et al. A prospective survey of the
characteristics, treatments and outcomes of patients with acute
coronary syndromes in Europe and the Mediterranean basin. The Euro
Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS).
Eur Heart J 2002;23:1190-201.
284.
Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment
in acute myocardial infarction: reappraisal of the golden hour.
Lancet 1996;348:771-5.
285.
Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality
and prehospital thrombolysis for acute myocardial infarction: a
meta-analysis. JAMA 2000;283:2686-92.
286.
Reimer KA, Jennings RB, Cobb FR, et al. Animal models for protecting
ischemic myocardium: results of the NHLBI Cooperative Study: comparison
of unconscious and conscious dog models. Circ Res 1985;56:651-65.
287.
Christian TF, Schwartz RS, Gibbons RJ. Determinants of infarct size
in reperfusion therapy for acute myocardial infarction. Circulation
1992;86:81-90.
288.
Huber KC, Bresnahan JF, Bresnahan DR, Pellikka PA, Behrenbeck T,
Gibbons RJ. Measurement of myocardium at risk by technetium-99m
sestamibi: correlation with coronary angiography. J Am Coll Cardiol
1992;19:67-73.
289. Klarich KW, Christian TF, Higano ST, Gibbons
RJ. Variability of myocardium at risk for acute myocardial infarction.
Am J Cardiol 1999;83:1191-5.
290.
Brodie BR, Stuckey TD, Wall TC, et al. Importance of time to reperfusion
for 30-day and late survival and recovery of left ventricular function
after primary angioplasty for acute myocardial infarction. J Am
Coll Cardiol 1998;32:1312-9.
291.
Brodie BR, Stone GW, Morice MC, et al, for the Stent Primary Angioplasty
in Myocardial Infarction Study Group. Importance of time to reperfusion
on outcomes with primary coronary angioplasty for acute myocardial
infarction (results from the Stent Primary Angioplasty in Myocardial
Infarction Trial). Am J Cardiol 2001;88:1085-90.
292.
Brodie BR, Stuckey TD, Muncy DB, et al. Importance of time-toreperfusion
in patients with acute myocardial infarction with and without cardiogenic
shock treated with primary percutaneous coronary intervention. Am
Heart J 2003;145:708-15.
293.
Antoniucci D, Valenti R, Migliorini A, et al. Relation of time to
treatment and mortality in patients with acute myocardial infarction
undergoing primary coronary angioplasty. Am J Cardiol 2002;89:1248-52.
294.
Berger PB, Ellis SG, Holmes DR, et al. Relationship between delay
in performing direct coronary angioplasty and early clinical outcome
in patients with acute myocardial infarction: results from the global
use of strategies to open occluded arteries in Acute Coronary Syndromes
(GUSTO-IIb) trial. Circulation 1999;100: 14-20.
295.
Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon
time and door-to-balloon time with mortality in patients undergoing
angioplasty for acute myocardial infarction. JAMA 2000;283:2941-7.
296. Zijlstra F, Patel A, Jones M, et al. Clinical
characteristics and outcome of patients with early (less than 2
h), intermediate (2-4 h) and late (greater than 4 h) presentation
treated by primary coronary angioplasty or thrombolytic therapy
for acute myocardial infarction. Eur Heart J 2002;23:550-7.
297.
Van de Werf F, Ardissino D, Betriu A, et al, for the Task Force
on the Management of Acute Myocardial Infarction of the European
Society of Cardiology. Management of acute myocardial infarction
in patients presenting with ST-segment elevation. The Task Force
on the Management of Acute Myocardial Infarction of the European
Society of Cardiology. Eur Heart J 2003;24:28-66.
298.
Krumholz HM, Chen J, Wang Y, Radford MJ, Chen YT, Marciniak TA.
Comparing AMI mortality among hospitals in patients 65 years of
age and older: evaluating methods of risk adjustment. Circulation
1999;99:2986-92.
299.
Granger CB, Goldberg RJ, Dabbous O, et al, for the Global Registry
of Acute Coronary Events Investigators. Predictors of hospital mortality
in the global registry of acute coronary events. Arch Intern Med
2003;163:2345-53.
300. Kent DM, Schmid CH, Lau J, Selker HP. Is
primary angioplasty for some as good as primary angioplasty for
all? J Gen Intern Med 2002;17:887-94.
301.
Hochman JS, Sleeper LA, Webb JG, et al, for the Should We Emergently
Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK)
Investigators. Early revascularization in acute myocardial infarction
complicated by cardiogenic shock. N Engl J Med 1999;341:625-34.
302.
Wu AH, Parsons L, Every NR, Bates ER, for the Second National Registry
of Myocardial Infarction. Hospital outcomes in patients presenting
with congestive heart failure complicating acute myocardial infarction:
a report from the Second National Registry of Myocardial Infarction
(NRMI-2). J Am Coll Cardiol 2002; 40:1389-94.
303.
Magid DJ, Calonge BN, Rumsfeld JS, et al, for the National Registry
of Myocardial Infarction 2 and 3 Investigators. Relation between
hospital primary angioplasty volume and mortality for patients with
acute MI treated with primary angioplasty vs thrombolytic therapy.
JAMA 2000;284:3131-8.
304.
Canto JG, Every NR, Magid DJ, et al, for the National Registry of
Myocardial Infarction 2 Investigators. The volume of primary angioplasty
procedures and survival after acute myocardial infarction. N Engl
J Med 2000;342:1573-80.
305.
Nallamothu BK, Bates ER. Percutaneous coronary intervention versus
fibrinolytic therapy in acute myocardial infarction: is timing (almost)
everything? Am J Cardiol 2003;92:824-6.
306.
Andersen HR, Nielsen TT, Rasmussen K, et al, for the DANAMI- 2 Investigators.
A comparison of coronary angioplasty with fibrinolytic therapy in
acute myocardial infarction. N Engl J Med 2003;349:733-42.
307.
Aversano T, Aversano LT, Passamani E, et al, for the Atlantic Cardiovascular
Patient Outcomes Research Team (C-PORT). Thrombolytic therapy vs
primary percutaneous coronary intervention for myocardial infarction
in patients presenting to hospitals without on-site cardiac surgery:
a randomized controlled trial. JAMA 2002;287:1943-51.
308.
Angeja BG, Gibson CM, Chin R, et al, for the Participants in the
National Registry of Myocardial Infarction 2-3. Predictors of door-to-balloon
delay in primary angioplasty. Am J Cardiol 2002;89:1156-61.
309.
Henriques JP, Haasdijk AP, Zijlstra F, for the Zwolle Myocardial
Infarction Study Group. Outcome of primary angioplasty for acute
myocardial infarction during routine duty hours versus during off-hours.
J Am Coll Cardiol 2003;41:2138-42.
310.
Spencer FA, Becker RC. Circadian variations in acute myocardial
infarction: patients or health care delivery? J Am Coll Cardiol
2003;41:2143-6.
311.
Armstrong PW, Antman EM. Coronary angioplasty versus fibrinolytic
therapy in acute myocardial infarction. N Engl J Med 2003;349:2167-9;
author reply.
312.
Herrick JB. Landmark article (JAMA 1912): clinical features of sudden
obstruction of the coronary arteries. JAMA 1983;250: 1757-65.
313.
Chazov EI, Matveeva LS, Mazaev AV, Sargin KE, Sadovskaia GV, Ruda
MI. [Intracoronary administration of fibrinolysin in acute myocardial
infarct.] Ter Arkh 1976;48:8-19.
314.
Aylward PE, Wilcox RG, Horgan JH, et al, for the GUSTO-I Investigators.
Relation of increased arterial blood pressure to mortality and stroke
in the context of contemporary thrombolytic therapy for acute myocardial
infarction: a randomized trial. Ann Intern Med 1996;125:891-900.
| 
